Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Annual NHI Price Cuts Draw Fire from All Sides at Ryukaikon Council
December 10, 2014
- Eculizumab, Bosentan Designated as Orphan Drugs
December 10, 2014
- Japan NIH to Have Drug Discovery Support Unit
December 9, 2014
- Paclitaxel OK’ed for External Review under Fast-Track Senshin-Iryo Scheme for Cancer Drugs
December 8, 2014
- Five SGLT-2 Inhibitors Undergoing Evaluation for Risk of Dehydration: PMDA
December 8, 2014
- Fee Cut Rule Needs Review before Debate on Annual NHI Price Revisions: MHLW Exec
December 4, 2014
- LDP Members Share Various Opinions on Social Security Issues
December 4, 2014
- Council Approves Subsidies for Retreatment with 3-Drug Combination Therapies Using Protease Inhibitors Other than Simeprevir
December 4, 2014
- ICH Makes Progress Toward Greater Inclusivity, Agrees to Establish Assembly at November Meeting in Lisbon
December 4, 2014
- Pharma Industry Girding for Post-Election Lobbying on R&D Tax Credit
December 3, 2014
- Kyowa Kirin’s Poteligeo to Receive Additional Indication for Incipient Untreated ATL, Will Be Added to mLSG15 Therapy
December 2, 2014
- Editor’s Pick: Five Healthcare News Headlines for Nov. 17 - 28
December 1, 2014
- PAFSC’s Second Committee Backs Approval of Novartis’s Secukinumab
December 1, 2014
- Japan’s 1st Orphan Regenerative Medicine Status Given to Skin-Derived Cell Sheet
December 1, 2014
- 13 APIs/23 Products Including Remicade Biosimilar Added to NHI Price List
November 28, 2014
- MHLW Warns of Hyperbilirubinemia in Patients on Sovriad
November 27, 2014
- Panel Gives Green Light to Draft Report Calling for Legal Regulations for Clinical Research
November 27, 2014
- Cabinet OKs Regenerative Medicine Guidelines
November 26, 2014
- New Pharma Law Takes Effect to Up the Ante for Safety
November 26, 2014
- Debates on Yearly NHI Price Cuts Put on Hold as Attention Turns to Election
November 26, 2014
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…